What Mango Sciences does

Mango Sciences, Inc. is a Boston-headquartered (with engineering operations in Bangalore, India) healthcare data science company founded in 2019/2020 that builds the proprietary Querent™ AI analytics platform to aggregate, structure, and analyze clinical patient data from emerging markets — primarily India — and convert it into real-world evidence and patient-access services. The platform applies predictive analytics, NLP (using transformer, BERT, GPT, and word2vec/doc2vec architectures), knowledge graphs (Neo4j-based), and deep learning to process both structured and unstructured EHR data from partner hospitals, addressing the structural underrepresentation of non-Caucasian populations in clinical research (cited as 86% of trial participants being Caucasian vs. 16% of world population).

The company operates a B2B2C model serving three distinct customer segments: hospitals and healthcare providers (Aster, Max Healthcare, Tata Memorial Hospital), life sciences companies (pharma/biotech seeking emerging-market RWE), and financial institutions (HDFC Bank, Axis Bank, Arogya Finance). Revenue is generated through subscription-based analytics services to hospitals and life sciences firms, managed-services revenue from patient affordability programs (including 0% EMI financing and value-based pricing rebates), and transaction fees from oncology-focused financial products co-developed with bank partners. The embedded footprint — 350+ hospitals and clinics covering approximately 28 million lives — functions as the primary data-asset base feeding the analytics product line.

Strategic momentum in 2025 includes the July 2025 strategic investment from Veeda Lifesciences and the December 2025 partnership with ImmunoACT to launch 'The Hope Initiative,' described as the world's first bridge-financing and value-based pricing plan for CAR-T therapy, offering 0% EMI plans and outcome-linked rebates up to ₹10 lakhs. The company is led by Co-Founder & CEO Dr. Mohit Misra and Co-Founder & CTO Vamsi Chandra Kasivajjala, with commercial leadership covering both North America and MENA/APAC, signaling intent to expand beyond India into South Asia and Africa.

Name

Mango Sciences

Legal name

Mango Sciences, Inc.

Website

https://mangosciences.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Mango Sciences operates the proprietary Querent™ AI analytics platform, aggregating clinical EHR data from 350+ hospitals and ~28 million lives in India to generate real-world evidence for life sciences companies, while enabling oncology patient access through hospital, pharma, and financial-institution partnerships.

Ownership category

akta.pro rank

Product category

Healthcare Data Analytics

NAICS

Software Publishers (5132)

SIC

Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF)

akta.pro secondary industry

Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)

Keywords

• Healthcare AI analytics
• Clinical data platform
• Real-world evidence
• Patient financing programs
• Emerging market health

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Data Analytics Services to Life Science Companies: Providing real-world evidence analytics, predictive insights, and AI-driven healthcare data services to pharmaceutical and life sciences companies seeking access to emerging market data.
2. Patient Benefits & Affordability Programs: Patient support programs including 0% interest EMI financing, value-based pricing, and outcome-based rebates for cancer therapies. Revenue generated through partnerships with financial institutions and healthcare providers, enabling patient access to high-cost oncology treatments.
3. Healthcare Provider Analytics & Operational Efficiency Solutions: AI-driven clinical insights and data analytics solutions sold to hospitals and healthcare providers to improve patient care quality and operational efficiency.
4. Oncology-focused Financial Products: Partnering with financial institutions to develop and enable oncology-focused loan products, creating new revenue streams for lenders while expanding patient access to targeted cancer therapies.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Mango Sciences develops and operates Querent™, a proprietary AI analytics platform that aggregates structured and unstructured clinical/EHR data from 350+ partner hospitals and clinics in India and other emerging markets (covering ~28 million lives) and applies predictive analytics, NLP, knowledge graph, and deep learning to generate real-world evidence. It complements this with a Patient Benefits Program and The Hope Initiative, which provide 0% interest EMI financing and value-based pricing for high-cost oncology treatments such as NexCAR19 CAR-T therapy, delivered through partnerships with hospitals, life science companies, and financial institutions.

Product overview

Mango Sciences operates as a platform-based healthcare AI company offering multiple integrated products: Querent™ serves as the core AI analytics platform providing predictive analytics, NLP, and knowledge graph capabilities for clinical data; the Patient Benefits Program provides financing solutions including 0% interest EMI plans and value-based pricing to improve treatment affordability; Mango Cancer Care serves as the patient-facing brand for cancer care access; and The Hope Initiative delivers specialized CAR-T therapy financing in partnership with ImmunoACT.

Differentiator

Problem solved

Functional benefit

Brands

• Mango Cancer Care: Patient-facing brand for cancer care services, accessible at mangocancercare.com
• Querent

Products and services

• Querent™ AI Analytics Platform Proprietary AI analytics platform that aggregates structured and unstructured clinical/EHR data from partner hospitals and clinics in India and other emerging markets and applies predictive analytics, NLP, knowledge graph, and deep learning to produce real-world evidence for healthcare providers and life sciences companies.
• Patient Benefits Program Patient affordability and access program that bundles financing and value-based pricing to help patients afford high-cost oncology treatments, delivered through Mango's hospital and financial institution partners.
• Mango Cancer Care Patient-facing service brand (mangocancercare.com) that connects cancer patients with financing options and treatment affordability programs available through Mango Sciences' hospital and bank partners.
• The Hope Initiative (CAR-T Bridge Financing) Specialized CAR-T therapy access program offering 0% interest EMI financing and value-based pricing rebates for ImmunoACT's NexCAR19 treatment for leukemia and lymphoma patients, operationalized with partner hospitals (including Tata Memorial) and financial institutions.

Quantifiable outcome

• Embedded in 350+ hospitals and clinics covering approximately 28 million lives across India.
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• ImmunoACTcoreStrategic or Co-development Partner · 5 December 2025Mango Sciences and ImmunoACT announced a strategic partnership to expand access and affordability of ImmunoACT's CAR-T therapy NexCAR19 for leukemia and lymphoma in India. The partnership introduces 'The Hope Initiative' offering patients 0% interest EMI financing plans and value-based pricing rebates of up to ₹10 lakhs if relapse occurs within 12 months. This is described as the world's first bridge financing plan for CAR-T therapy.
• AstercoreStrategic or Co-development PartnerAster is listed as a trusted hospital collaborator and key partner on Mango Sciences' Solutions for Hospitals page. Aster's hospital network provides clinical data for Mango's analytics platform and serves as a delivery channel for patient access programs.
• Max HealthcarecoreStrategic or Co-development PartnerMax Healthcare is listed as a trusted hospital collaborator on Mango Sciences' Solutions for Hospitals page. The partnership enables data-driven oncology solutions and access to innovative cancer treatments through Mango's patient benefits program.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Aetion: Aetion provides a real-world evidence analytics platform used by life-sciences companies and regulators to generate evidence from clinical and claims data. Like Mango Sciences, it sells RWE software to pharma and payers, but it focuses on mature markets rather than emerging-market EHR aggregation.
• TriNetX: TriNetX operates a global federated clinical research network that aggregates EHR data from hospitals for pharma-sponsored studies. It is a direct competitor for life-sciences RWE contracts, though its network is primarily U.S./EU-centric whereas Mango is India-first.
• Datavant: Datavant connects and de-identifies health data across providers and life-sciences companies to enable clinical research. Mango's hospital network and data integration for RWE generation makes it a comparable player, though Mango combines data connectivity with proprietary analytics on top.

Broad incumbents

• IQVIA: IQVIA is the global leader in clinical research, RWE, and life-sciences data services. It is comparable to Mango as a potential buyer and adjacent competitor for life-sciences RWE contracts, though Mango specializes in emerging-market datasets that IQVIA historically under-serves.
• Tempus: Tempus is an AI-driven precision medicine company combining multi-modal clinical and molecular data to support oncology drug development and care delivery. Mango's oncology-focused EHR analytics and patient access programs are comparable, though Tempus operates at much larger scale in the U.S. and Europe.
• Flatiron Health: Flatiron Health aggregates oncology EHR data and sells real-world evidence to life-sciences companies and regulators. Mango's emerging-market clinical data network and oncology focus position it as a complementary or future-competitive player in the same oncology RWE category.
• Health Catalyst: Health Catalyst is a healthcare analytics platform provider serving hospitals and life-sciences companies with data warehousing, population health, and analytics. Mango's hospital analytics and life-sciences RWE offerings overlap, though Health Catalyst's installed base is concentrated in U.S. health systems.

Emerging players

• Atropos Health: Atropos Health generates real-world evidence on-demand from de-identified EHR data using AI/ML, primarily for U.S. health systems and life-sciences companies. Mango applies similar principles — turning EHR data into actionable evidence — but with a geographic focus on emerging markets.
• Innovaccer: Innovaccer is a healthcare data platform company aggregating EHR, claims, and other clinical data to enable providers, payers, and life-sciences companies. Mango's hospital-focused data aggregation and analytics are similar, though Innovaccer is more established in the U.S. provider and payer market.

Regional players

• Tata 1mg (Tata Digital Healthcare): Tata 1mg is an India-based digital health and diagnostics platform with access to patient health data and pharmacy transactions. It is a comparable India-centric healthcare data player, though its primary focus is consumer pharmacy rather than hospital EHR aggregation and RWE.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/mango-sciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds7 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mango Sciences